Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pre Procedural High Serum Visfatin and Tumor Necrosis Factors "Alpha" Might Predict Recurrent Atrial Fibrillation After Catheter Ablation

NCT05114772 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT05114772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05114772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pre Procedural High Serum Visfatin and Tumor Necrosis Factors "Alpha" Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
Lead sponsor
Tanta University
Phase
Not applicable
Overall status
Completed
Start date
July 1, 2019
Completion date
August 1, 2021
Enrollment
117 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation